Crude, adjusted and propensity-adjusted rate ratios for the risk of uveitis and scleritis among first-time users of oral bisphosphonate
| Outcome | Crude RR | Adjusted* RR | Propensity-adjusted* RR |
|---|---|---|---|
| Uveitis | 1.54 (1.33–1.78) | 1.45 (1.25–1.68) | 1.50 (1.29–1.73) |
| Scleritis | 1.85 (1.68–2.05) | 1.51 (1.34–1.68) | 1.53 (1.39–1.70) |
Note: RR = rate ratio.
↵* Adjusted for age at index, sex, calendar time, use of sulfa-containing drugs, and comorbidities (ankylosing spondylitis, psoriasis, inflammatory bowel disease, rheumatoid arthritis, diabetes, systemic lupus erythematosus, sarcoidosis, multiple sclerosis).